Reference
Serna-Blasco R, et al. KRAS p.G12C mutation occurs in 1% of EGFR-mutated advanced non-small-cell lung cancer patients progressing on a first-line treatment with a tyrosine kinase inhibitor. ESMO Open 6: 100279, No. 5, Oct 2021. Available from: URL: http://doi.org/10.1016/j.esmoop.2021.100279
Rights and permissions
About this article
Cite this article
Afatinib. Reactions Weekly 1891, 15 (2022). https://doi.org/10.1007/s40278-022-09267-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-022-09267-6